By Sneha S K April 2 (Reuters) - Immunovant said on Thursday that its therapy failed to reduce eye bulging when tested in ...

By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics shares slumped 34% to an eight-month low on Monday after its ...

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

Viridian Therapeutics said on Monday its experimental drug met ​the main goal ‌in late-stage study, when tested in patients with active thyroid eye disease. The injectable ‌drug, ​elegrobart, was ...

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to ...

If you have thyroid eye disease (TED), you may have experienced emotional or mental issues, such as anxiety, body image distress, depression, and emotional exhaustion, that are often associated with ...

Viridian Therapeutics recently reported positive topline Phase 3 REVEAL-1 results for elegrobart in active thyroid eye disease, with both four-week and eight-week subcutaneous dosing regimens ...

Treatment options today can slow disease progression and ease symptoms. Along with medical care, lifestyle adjustments can also make a big difference in your daily comfort and quality of life. Here ...

Shares of Immunovant moved lower in premarket trading after the clinical-stage immunology company said its batoclimab drug candidate failed in a pair of late-stage studies in thyroid eye disease.

Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease March 30, ...